Literature DB >> 5492847

Two new pathological haemoglobins: Olmsted beta 141 (H19) Leu leads to Arg and Malmö beta 97 (FG4) His leads to Gln.

P A Lorkin, H Lehmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5492847      PMCID： PMC1179554          DOI： 10.1042/bj1190068pa

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


× No keyword cloud information.
  6 in total

1.  Molecular pathology of human haemoglobin.

Authors:  M F Perutz; H Lehmann
Journal:  Nature       Date:  1968-08-31       Impact factor: 49.962

2.  Three-dimensional Fourier synthesis of horse oxyhaemoglobin at 2.8 A resolution: (1) x-ray analysis.

Authors:  M F Perutz; H Miurhead; J M Cox; L C Goaman; F S Mathews; E L McGandy; L E Webb
Journal:  Nature       Date:  1968-07-06       Impact factor: 49.962

3.  Three-dimensional Fourier synthesis of horse oxyhaemoglobin at 2.8 A resolution: the atomic model.

Authors:  M F Perutz; H Muirhead; J M Cox; L C Goaman
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

4.  Hemoglobin-Bibba or alpha-2-136Pro-beta 2, an unstable alpha chain abnormal hemoglobin.

Authors:  E F Kleihauer; C A Reynolds; A M Dozy; J B Wilson; R R Moores; M P Berenson; C S Wright; T H Huisman
Journal:  Biochim Biophys Acta       Date:  1968-01-22

5.  Three families with unstable hemoglobinopathies (Köln, Olmsted and Santa Ana) causing hemolytic anemia with inclusion bodies and pigmenturia.

Authors:  V F Fairbanks; R W Opfell; E O Burgert
Journal:  Am J Med       Date:  1969-03       Impact factor: 4.965

6.  Variations in the structure of human haemoglobin. With particular reference to the unstable haemoglobins.

Authors:  H Lehmann; R W Carrell
Journal:  Br Med Bull       Date:  1969-01       Impact factor: 4.291
  6 in total
  1 in total

1.  At high altitude in the Netherlands: secondary erythrocytosis due to HB-Malmö.

Authors:  Bart Santbergen; Cees van der Heul
Journal:  BMJ Case Rep       Date:  2014-03-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.